Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557791 | 1.00 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5326495 | 1.00 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623032 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5821483 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL10958796 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623037 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623366 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1622513 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5185943 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL679503 | 0.99 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085839-A1 | COMPOSITION AND METHOD FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-04-30 | — | — | WO | claimed |
| WO-2026085839-A1 | COMPOSITION AND METHOD FOR CARING FOR KERATIN MATERIALS | L'OREAL (FR) | 2026-04-30 | — | — | WO | disclosed |
| CN-107428665-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-15 | — | — | CN | disclosed |
| CN-107406363-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-08 | — | — | CN | disclosed |
| CN-107709377-B | Curable composition | 东亚合成株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-107709376-B | Curable composition | 东亚合成株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-107922555-B | Curable composition | 东亚合成株式会社 | 2020-08-28 | — | — | CN | disclosed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20180105483-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | TOAGOSEI CO., LTD. (JP) | 2018-04-19 | — | — | US | disclosed |
| EP-3281933-A1 | (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2018-02-14 | — | — | EP | disclosed |
| EP-3269700-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | Toagosei Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| EP-3133058-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-1320373-B1 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE | ANASTASSIADES TASSOS P (CA) | 2007-01-31 | — | — | EP | disclosed |
| EP-1320373-A2 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE | Anastassiades, Tassos, P. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6479469-B2 | N-ACYLATED-2-GLUCOSAMINE DERIVATIVES FOR TREATING OSTEOARTHRITIS/INFLAMMATORY ARTHRITIS, AND ENHANCING CARTILAGE FORMULATION, CHONDROCYTE CELL PROLIFERATION AND GLYCOSAMINOGLYCAN PRODUCTION | ANACOTI LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-20020045597-A1 | Treatment of arthritis and compositions therefore | ANACOTI LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| WO-2002017890-A2 | TREATMENT OF ARTHRITIS AND COMPOSITIONS THEREFORE CONTAINING A N-ACYLATED-2-GLUCOSAMINE DERIVATIVE | ANASTASSIADES TASSOS P (CA) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045597-A1 | Treatment of arthritis and compositions therefore | COL2A1, B3GNT2, CSGALNACT1 | MEN1 4617/4885KMT2A 3399/4885DEGS1 892/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | MEN1 195/4885KMT2A 279/4885DEGS1 191/4885 |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | MMAB, AMD1, ADH5 | MEN1 312/4885KMT2A 518/4885DEGS1 1590/4885 |
| US-20180105483-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | MMAB, ADH5, ADH1A | MEN1 459/4885KMT2A 297/4885DEGS1 3261/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | MEN1 677/4885KMT2A 131/4885DEGS1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.